{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# GraphRAG Retrieval Evaluation"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Purpose\n",
    "The code implements an enhanced document retrieval system that combines vector similarity search with graph-based traversal to find relevant document chunks. Here's a detailed breakdown:\n",
    "\n",
    "1. **Vector Search & Similarity Scoring**\n",
    " - Converts the input query into a vector embedding\n",
    " - Performs similarity search against entity nodes in Neo4j\n",
    " - Creates a sorted dictionary of entity IDs and their similarity scores\n",
    " - Filters results based on a similarity threshold (default 0.8)\n",
    "\n",
    "2. **Graph Traversal Strategy**\n",
    "```sql\n",
    "    MATCH path = (n:Chunk)-[*1..{max_hops}]->(m:`__Entity__`)\n",
    "    WHERE m.id IN $ids\n",
    "```\n",
    " - Finds paths from document chunks to relevant entities\n",
    " - Limits path length to control traversal depth\n",
    " - Only considers entities that met the similarity threshold\n",
    "\n",
    "3. **Relevance Calculation**\n",
    "```sql\n",
    "    WITH n, min(length(path)) as distance, m\n",
    "    WITH n, distance, m.id as entity_id\n",
    "    WITH n, distance, entity_id, \n",
    "            CASE \n",
    "            WHEN entity_id IN $ids \n",
    "            THEN $similarity_scores[entity_id]\n",
    "            END as similarity\n",
    "```\n",
    " - Calculates shortest path length to each entity\n",
    " - Preserves original similarity scores from vector search\n",
    " - Combines structural proximity (distance) with semantic similarity\n",
    "\n",
    "4. **Result Ordering**\n",
    "```sql\n",
    "    ORDER BY similarity DESC, distance\n",
    "```\n",
    " - Prioritizes chunks with higher semantic similarity\n",
    " - Uses path distance as a secondary sorting criterion\n",
    " - Ensures most relevant chunks appear first\n",
    "\n",
    "5. **Output Format**\n",
    "```sql\n",
    "    RETURN n.text, n.fileName, n.page_number, n.position, entity_id, similarity\n",
    "```\n",
    " - Returns comprehensive chunk metadata:\n",
    "    - Text content\n",
    "    - Source file name\n",
    "    - Page number\n",
    "    - Position in document\n",
    "    - Associated entity ID\n",
    "    - Similarity score\n",
    "\n",
    "## Key Features\n",
    "- Hybrid retrieval approach combining:\n",
    "    - Vector-based semantic search\n",
    "    - Graph-based structural relationships\n",
    "- Configurable parameters:\n",
    "    - Similarity threshold\n",
    "    - Maximum path length\n",
    "    - Result limit\n",
    "- Deduplication of chunks\n",
    "- Ordered results by relevance\n",
    "- Rich metadata for each chunk"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 0: environment set up"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "jupyter": {
     "is_executing": true
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "\n",
    "import os\n",
    "from langchain_neo4j import Neo4jGraph\n",
    "from libs import create_vector_index\n",
    "import pandas as pd\n",
    "from conn import connect2Googlesheet,retrieval_rel_docs, get_avg_similarity_df,get_concatenate_df,clean_retrieved_files,apply_metrics,plot_metrics_and_roc\n",
    "from libs import context_builder, chunk_finder, enhanced_chunk_finder\n",
    "# Force reload of the .env file\n",
    "load_dotenv()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Connected to Neo4j database successfully.\n"
     ]
    }
   ],
   "source": [
    "# Connect to Neo4j database\n",
    "try:\n",
    "    graph = Neo4jGraph(\n",
    "        url=os.getenv(\"NEO4J_URL\"),\n",
    "        username=os.getenv(\"NEO4J_USERNAME\"),\n",
    "        password=os.getenv(\"NEO4J_PASSWORD\")\n",
    "    )\n",
    "    print(\"Connected to Neo4j database successfully.\")\n",
    "except ValueError as e:\n",
    "    print(f\"Could not connect to Neo4j database: {e}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 1: Create vector index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "âœ… Index 'entities' already exists with correct dimensions: 384\n"
     ]
    }
   ],
   "source": [
    "create_vector_index(graph, \"entities\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 2: Load questions from google sheet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>condition</th>\n",
       "      <th>number</th>\n",
       "      <th>docs</th>\n",
       "      <th>Question</th>\n",
       "      <th>Mahmud's Note</th>\n",
       "      <th>status</th>\n",
       "      <th>comments</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>1</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>Does early administration of neuromuscular blo...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>2</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>Do patients with severe ARDS being treated wit...</td>\n",
       "      <td>Replace</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>3</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>In patients with moderate to severe ARDS, does...</td>\n",
       "      <td>Maybe this question: In patients with moderate...</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>4</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have ...</td>\n",
       "      <td>Local question (not sure if this is the aim of...</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Wrong concept since PEEP by itself is mandator...</td>\n",
       "      <td>Does the use of neuromuscular blockers in pati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>5</td>\n",
       "      <td>FACTT</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservat...</td>\n",
       "      <td>Local question (not sure if this is the aim of...</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Check if studies defined conservative by CVP &lt;...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  condition  number      docs  \\\n",
       "0      ARDS       1  ACURASYS   \n",
       "1      ARDS       2  ACURASYS   \n",
       "2      ARDS       3      ROSE   \n",
       "3      ARDS       4      ROSE   \n",
       "4      ARDS       5     FACTT   \n",
       "\n",
       "                                            Question  \\\n",
       "0  Does early administration of neuromuscular blo...   \n",
       "1  Do patients with severe ARDS being treated wit...   \n",
       "2  In patients with moderate to severe ARDS, does...   \n",
       "3  Do patients with moderate-to-severe ARDS have ...   \n",
       "4  Among patients with ALI/ARDS, does a conservat...   \n",
       "\n",
       "                                       Mahmud's Note status  \\\n",
       "0                                               Like          \n",
       "1                                            Replace  fixed   \n",
       "2  Maybe this question: In patients with moderate...  fixed   \n",
       "3  Local question (not sure if this is the aim of...  fixed   \n",
       "4  Local question (not sure if this is the aim of...  fixed   \n",
       "\n",
       "                                            comments  \\\n",
       "0                                                      \n",
       "1                                                      \n",
       "2                                                      \n",
       "3  Wrong concept since PEEP by itself is mandator...   \n",
       "4  Check if studies defined conservative by CVP <...   \n",
       "\n",
       "                                                      \n",
       "0                                                     \n",
       "1                                                     \n",
       "2                                                     \n",
       "3  Does the use of neuromuscular blockers in pati...  \n",
       "4                                                     "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "spreadsheet = connect2Googlesheet()\n",
    "\n",
    "# Select the worksheet: relevance\n",
    "worksheet = spreadsheet.get_worksheet(2)  \n",
    "\n",
    "# Get all records as a list of dictionaries\n",
    "data = worksheet.get_all_records()\n",
    "\n",
    "# Convert to Pandas DataFrame\n",
    "df_MedQ = pd.DataFrame(data)\n",
    "df_MedQ.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 3: Relevance check for top K questions"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The [*1..{max_hops}] syntax in the Cypher query defines a variable-length relationship pattern in Neo4j.\n",
    "**Syntax Explanation**\n",
    "- `*` indicates a variable-length path\n",
    "- 1..{max_hops} specifies the range:\n",
    "    - 1 is the minimum length\n",
    "    - {max_hops} is the maximum length (passed as a parameter)\n",
    "\n",
    "**Purpose**\n",
    "1. Path Flexibility: It allows finding relationships between nodes that are both:\n",
    "    - Directly connected (1 hop)\n",
    "    - Indirectly connected (up to max_hops steps away)\n",
    "2. Example with max_hops=2:\n",
    "```python\n",
    "    (Chunk)-->(Entity)           // 1 hop\n",
    "    (Chunk)-->(Node)-->(Entity)  // 2 hops\n",
    "```\n",
    "3. Use Case in the Code:\n",
    "- The query finds chunks that are connected to relevant entities either:\n",
    "    - Directly (1 relationship away)\n",
    "    - Through intermediate nodes (up to max_hops relationships away)\n",
    "- This broadens the search context while maintaining control over the search depth\n",
    "\n",
    "**Practical Impact**\n",
    "```python\n",
    "    # With max_hops = 1 (direct connections only)\n",
    "    Chunk -> Entity\n",
    "\n",
    "    # With max_hops = 2 (includes indirect connections)\n",
    "    Chunk -> IntermediateNode -> Entity\n",
    "```\n",
    "This flexibility is particularly useful in knowledge graphs where relevant information might be connected through intermediate concepts or relationships."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Set pandas display options to show the full text content\n",
    "pd.set_option('display.max_colwidth', None)\n",
    "pd.set_option('display.max_rows', None)\n",
    "pd.set_option('display.max_columns', None)\n",
    "# seeting up hyperparameters\n",
    "topk = 36 # 36 questions in total\n",
    "limit = 20\n",
    "similarity_threshold = 0.8 \n",
    "max_hops = 1"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Uncomment the Following Code to Get `results_df` Using `retrieval_rel_docs`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "#results_df = retrieval_rel_docs(graph, df_MedQ, top_k=topk , limit = limit ,similarity_threshold = similarity_threshold , max_hops = max_hops) # Retrieve relevant documents for each question\n",
    "# results_df.to_csv('./outputs/retrieved_docs_results.csv', index=False)\n",
    "#results_df"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 4: Compare Retrieval and Annotation Using Binary Metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question Number</th>\n",
       "      <th>Question</th>\n",
       "      <th>Annotated Docs</th>\n",
       "      <th>Retrieved Docs</th>\n",
       "      <th>Avg Similarity</th>\n",
       "      <th>Accuracy</th>\n",
       "      <th>Precision</th>\n",
       "      <th>Recall</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Does early administration of neuromuscular blocking agents increases the ventilator free days?</td>\n",
       "      <td>NBSARDS, ESCNBC, ROSE, ACURASYS, TOF-ARDS, PVOEMVRARDS, ENB, EDPMARDSLPMV, LSPA</td>\n",
       "      <td>ESCPARDS, FMWSCPARDS, RARDS, ARDSSRDRFMS, EDvsLSMENDS, DDS, APROCCHSS, LSPA, ETSDMV</td>\n",
       "      <td>0.852377</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?</td>\n",
       "      <td>NBSARDS, ESCNBC, ROSE, ETSDMV, ACURASYS, TOF-ARDS, PVOEMVRARDS, ENB, EDPMARDSLPMV, LSPA</td>\n",
       "      <td>ESCPARDS, PVOEMVRARDS, TOF-ARDS, HARDST, OSCILLATE, NBSARDS, NEvsVP, LSPA, ETSDMV, ENB, APV, CEIIUPPSARDS, ACURASYS</td>\n",
       "      <td>0.863792</td>\n",
       "      <td>0.277778</td>\n",
       "      <td>0.384615</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?</td>\n",
       "      <td>NBSARDS, ESCNBC, ROSE, ETSDMV, PVOEMVRARDS, TOF-ARDS, ENB</td>\n",
       "      <td>ESCPARDS, PVOEMVRARDS, TOF-ARDS, HARDST, NBSARDS, LSPA, ETSDMV, ENB, APV, ACURASYS</td>\n",
       "      <td>0.855618</td>\n",
       "      <td>0.307692</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.571429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have a significance difference in mortality rate beween patients who recieved an early and continous cisatracurium infusion than those with usual care approach with lighter sedation targets?</td>\n",
       "      <td>NBSARDS, ESCNBC, ROSE, ETSDMV, PVOEMVRARDS, TOF-ARDS, ENB</td>\n",
       "      <td>RARDS, HARDST, APV</td>\n",
       "      <td>0.817095</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?</td>\n",
       "      <td>ARDSSRDRFMS, FMWSCPARDS, PAC-in-FACTT, FACTT</td>\n",
       "      <td>FMWSCPARDS</td>\n",
       "      <td>0.842748</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?</td>\n",
       "      <td>ARDSSRDRFMS, FMWSCPARDS, PAC-in-FACTT, FACTT</td>\n",
       "      <td>FMWSCPARDS, RARDS, ARDSSRDRFMS, FACTT, PAC in FACTT</td>\n",
       "      <td>0.846286</td>\n",
       "      <td>0.375000</td>\n",
       "      <td>0.428571</td>\n",
       "      <td>0.750000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?</td>\n",
       "      <td>DLASPEEPvsARDSNET, DIHRFARDSNET, APV, ARDSNet</td>\n",
       "      <td>RARDS, ARDSNet, HARDST, NBSARDS, LSPA, ENB, CEIIUPPSARDS, ACURASYS</td>\n",
       "      <td>0.846128</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?</td>\n",
       "      <td>DLASPEEPvsARDSNET, SPICE-III, APV, AID-ICU, DIHRFARDSNET, ARDSNet</td>\n",
       "      <td>ESCPARDS, FMWSCPARDS, ARDSNet, ARDSSRDRFMS, ESDDVCIP, HARDST, EDvsLSMENDS, DLASPEEPvsARDSNET, APROCCHSS, LSPA, ETSDMV, ENB, ACURASYS</td>\n",
       "      <td>0.831315</td>\n",
       "      <td>0.055556</td>\n",
       "      <td>0.076923</td>\n",
       "      <td>0.166667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Prone positioning sessions in patients with severe ARDS significantly decreased mortality?</td>\n",
       "      <td>PROSEVA, CEIIUPPSARDS, ETSDMV, PPATDSHMA, EDPMARDSLPMV</td>\n",
       "      <td>ESCPARDS, PVOEMVRARDS, TOF-ARDS, PROSEVA, HARDST, NBSARDS, NEvsVP, LSPA, ETSDMV, ENB, APV, CEIIUPPSARDS, ACURASYS</td>\n",
       "      <td>0.862781</td>\n",
       "      <td>0.200000</td>\n",
       "      <td>0.230769</td>\n",
       "      <td>0.600000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal voulme decrease mortality?</td>\n",
       "      <td>SEDCOM, HDDSICU, SPICE-III, OSCILLATE, AID-ICU, MIND-USA</td>\n",
       "      <td>PLMALDHSS, RARDS, ENB, ARDSNet, OSCILLATE, NBSARDS, LSPA, BMIMSARDS, CEIIUPPSARDS</td>\n",
       "      <td>0.852191</td>\n",
       "      <td>0.071429</td>\n",
       "      <td>0.111111</td>\n",
       "      <td>0.166667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?</td>\n",
       "      <td>SEDCOM, ANNANE, SPICE-III, ADRENAL, CORTICUS, APPROCCHSS, AID-ICU, MIND-USA</td>\n",
       "      <td>Rivers-Trial, ANNANE, THvsTN, PLMALDHSS, FRESHS, CORTICUS, PROWESS-SHOCK, IDEAL-ICU, DDS, APROCCHSS, VASST, ADRENAL, EHPSS</td>\n",
       "      <td>0.838482</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.230769</td>\n",
       "      <td>0.375000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>A 7-day treatment with low doses of steriods significantly reduced the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events</td>\n",
       "      <td>SEDCOM, HDDSICU, ANNANE, RDSCI, SPICE-III, ETSDMV, SMDLTSWCI, DDMLSMVICP, ADRENAL, EDvsLSMENDS, CORTICUS, APPROCCHSS, AID-ICU, MIND-USA, ESDDVCIP</td>\n",
       "      <td>ADRENAL</td>\n",
       "      <td>0.830840</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?</td>\n",
       "      <td>CORTICUS, APPROCCHSS, ADRENAL, ANNANE</td>\n",
       "      <td>ANNANE, PLMALDHSS, CORTICUS, APROCCHSS, ADRENAL</td>\n",
       "      <td>0.825184</td>\n",
       "      <td>0.125000</td>\n",
       "      <td>0.200000</td>\n",
       "      <td>0.250000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>Does steriods hasten the reversal of shock in patients whom had septic shock reversed?</td>\n",
       "      <td>CORTICUS, APPROCCHSS, ADRENAL, ANNANE</td>\n",
       "      <td>ADRENAL, ANNANE, FRESHS, SADASS, IDEAL-ICU, PROWESS-SHOCK, DDS, APROCCHSS, VASST, CORTICUS</td>\n",
       "      <td>0.822311</td>\n",
       "      <td>0.076923</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>0.250000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>Does early administration of acetaminophen to treat fever affect the number of ICU-free days</td>\n",
       "      <td>ESDDVCIP, HEAT</td>\n",
       "      <td>ITMNCA, HEAT, TTM2</td>\n",
       "      <td>0.818425</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?</td>\n",
       "      <td>PROWESS, ESDDVCIP, PROWESS-SHOCK</td>\n",
       "      <td>PROWESS, PLMALDHSS, SADASS, RDSCI, EDvsLSMENDS, APROCCHSS, ETSDMV, CABS</td>\n",
       "      <td>0.848925</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>0.125000</td>\n",
       "      <td>0.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival</td>\n",
       "      <td>RUSGATICUD, SAFE, ALBIOS</td>\n",
       "      <td>SS3vsSS2, ALBIOS, ProCESS, ProMISe, ULS, EHPSS</td>\n",
       "      <td>0.822312</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?</td>\n",
       "      <td>SAFE, ALBIOS</td>\n",
       "      <td>FEAST, FRESHS, SADASS, SAFE, HEAT, SEPSISPAM</td>\n",
       "      <td>0.820228</td>\n",
       "      <td>0.142857</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>Hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome</td>\n",
       "      <td>RUSGATICUD, ProMISe, AID-ICU</td>\n",
       "      <td>Rivers-Trial, MPOHCAUSPITHRCA, ProMISe, FACTT, DDS, PAC in FACTT</td>\n",
       "      <td>0.850829</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>0.125000</td>\n",
       "      <td>0.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?</td>\n",
       "      <td>PROWESS, ESDDVCIP, PROWESS-SHOCK</td>\n",
       "      <td>APROCCHSS, PROWESS-SHOCK, ANNANE, PLMALDHSS</td>\n",
       "      <td>0.810169</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>21</td>\n",
       "      <td>In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?</td>\n",
       "      <td>AID-ICU, TTM, TTM2</td>\n",
       "      <td>ITMNCA, CETHACA, THvsTN, HNPCASR, TTM2, TCAIHCA, HEAT</td>\n",
       "      <td>0.862389</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>22</td>\n",
       "      <td>In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33Â°C provide any benefit compared with a targeted temperature of 36Â°C?</td>\n",
       "      <td>TTM, TTM2</td>\n",
       "      <td>ITMNCA, CETHACA, THvsTN, MPOHCAUSPITHRCA, HNPCASR, TTM2, TCAIHCA, HEAT</td>\n",
       "      <td>0.868727</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>23</td>\n",
       "      <td>Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?</td>\n",
       "      <td>ESDDVCIP, HACA</td>\n",
       "      <td>ITMNCA, CETHACA, THvsTN, RIC, EXACT, HNPCASR, TCAIHCA, HEAT, HACA</td>\n",
       "      <td>0.852751</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>0.111111</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>24</td>\n",
       "      <td>Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?</td>\n",
       "      <td>RUSGATICUD, SPICE-III, DDMLSMVICP, AID-ICU, RAEATICU, MIND-USA, AUDDICU</td>\n",
       "      <td>DDMLSMVICP, MIND-USA, RUSGATICUD, AID-ICU, AMTD, EDvsLSMENDS, DIICU, LSPA</td>\n",
       "      <td>0.855470</td>\n",
       "      <td>0.363636</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.571429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>25</td>\n",
       "      <td>Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?</td>\n",
       "      <td>MIND-USA, SEDCOM, RAEATICU, RUSGATICUD</td>\n",
       "      <td>MIND-USA, RAEATICU, RUSGATICUD, AID-ICU, AMTD, EDvsLSMENDS, DIICU</td>\n",
       "      <td>0.817754</td>\n",
       "      <td>0.222222</td>\n",
       "      <td>0.285714</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>26</td>\n",
       "      <td>Is there more adverse events in ICU patients who recieved early dexmedetomidine?</td>\n",
       "      <td>HDDSICU, RDSCI, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, AID-ICU, MIND-USA, DIICU, ESDDVCIP</td>\n",
       "      <td>RAEATICU, SEDCOM, RDSCI, DDS, HDDSICU</td>\n",
       "      <td>0.844013</td>\n",
       "      <td>0.066667</td>\n",
       "      <td>0.200000</td>\n",
       "      <td>0.090909</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27</td>\n",
       "      <td>Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?</td>\n",
       "      <td>SEDCOM, RDSCI, RUSGATICUD, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, RAEATICU, MIND-USA, ESDDVCIP</td>\n",
       "      <td>ESDDVCIP, RDSCI, EDvsLSMENDS, LSPA, ETSDMV, HDDSICU</td>\n",
       "      <td>0.855043</td>\n",
       "      <td>0.214286</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.272727</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>28</td>\n",
       "      <td>Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?</td>\n",
       "      <td>SEDCOM, HDDSICU, RDSCI, RUSGATICUD, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, RAEATICU, MIND-USA, DIICU, ESDDVCIP</td>\n",
       "      <td>DDMLSMVICP, ESDDVCIP, RDSCI, EDvsLSMENDS, LSPA, ETSDMV, SMDLTSWCI, PESDCOMV, HDDSICU</td>\n",
       "      <td>0.849549</td>\n",
       "      <td>0.294118</td>\n",
       "      <td>0.555556</td>\n",
       "      <td>0.384615</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>29</td>\n",
       "      <td>Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?</td>\n",
       "      <td>SEDCOM, HDDSICU, RDSCI, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, DIICU, ESDDVCIP</td>\n",
       "      <td>RAEATICU, SEDCOM, RDSCI, DDS, HDDSICU</td>\n",
       "      <td>0.814198</td>\n",
       "      <td>0.153846</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.200000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>30</td>\n",
       "      <td>At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?</td>\n",
       "      <td>SEDCOM, HDDSICU, RDSCI, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, RAEATICU, DIICU, ESDDVCIP</td>\n",
       "      <td>ESDDVCIP, RDSCI, EDvsLSMENDS, ETSDMV, HDDSICU</td>\n",
       "      <td>0.839352</td>\n",
       "      <td>0.230769</td>\n",
       "      <td>0.600000</td>\n",
       "      <td>0.272727</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>31</td>\n",
       "      <td>Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate?</td>\n",
       "      <td>ESDDVCIP, ESCPARDS</td>\n",
       "      <td>ESCPARDS, PVOEMVRARDS, TOF-ARDS, HARDST, NBSARDS, NEvsVP, LSPA, ENB, ACURASYS</td>\n",
       "      <td>0.843222</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>32</td>\n",
       "      <td>Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?</td>\n",
       "      <td>ESDDVCIP, LCOTARDS</td>\n",
       "      <td>ESCPARDS, PVOEMVRARDS, TOF-ARDS, HARDST, NBSARDS, NEvsVP, LSPA, ENB, CEIIUPPSARDS, ACURASYS, PTARDS</td>\n",
       "      <td>0.841507</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>33</td>\n",
       "      <td>Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??</td>\n",
       "      <td>ESDDVCIP, MHNOCA</td>\n",
       "      <td>THvsTN, TTM2</td>\n",
       "      <td>0.843517</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>34</td>\n",
       "      <td>Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?</td>\n",
       "      <td>BTCSCA</td>\n",
       "      <td>CETHACA, HACA-LA, THvsTN, RIC, EXACT, CAC, TTM2, OHCA, IHCA, BTCSCA, HACA</td>\n",
       "      <td>0.833451</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>35</td>\n",
       "      <td>Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?</td>\n",
       "      <td>ESDDVCIP, SPICE-III, HDDSICU, OTCSCA</td>\n",
       "      <td>CETHACA, THvsTN, RIC, EXACT, CAC, TTM2, TCAIHCA, BTCSCA, HACA</td>\n",
       "      <td>0.845643</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>36</td>\n",
       "      <td>is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?</td>\n",
       "      <td>SEDCOM, HDDSICU, DPSMVAS, RDSCI, ETSDMV, SPICE-III, DDMLSMVICP, EDvsLSMENDS, RAEATICU, MIND-USA, DIICU, ESDDVCIP</td>\n",
       "      <td>RDSCI, HDDSICU</td>\n",
       "      <td>0.820172</td>\n",
       "      <td>0.076923</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.083333</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Question Number  \\\n",
       "0                 1   \n",
       "1                 2   \n",
       "2                 3   \n",
       "3                 4   \n",
       "4                 5   \n",
       "5                 6   \n",
       "6                 7   \n",
       "7                 8   \n",
       "8                 9   \n",
       "9                10   \n",
       "10               11   \n",
       "11               12   \n",
       "12               13   \n",
       "13               14   \n",
       "14               15   \n",
       "15               16   \n",
       "16               17   \n",
       "17               18   \n",
       "18               19   \n",
       "19               20   \n",
       "20               21   \n",
       "21               22   \n",
       "22               23   \n",
       "23               24   \n",
       "24               25   \n",
       "25               26   \n",
       "26               27   \n",
       "27               28   \n",
       "28               29   \n",
       "29               30   \n",
       "30               31   \n",
       "31               32   \n",
       "32               33   \n",
       "33               34   \n",
       "34               35   \n",
       "35               36   \n",
       "\n",
       "                                                                                                                                                                                                                                   Question  \\\n",
       "0                                                                                                                                            Does early administration of neuromuscular blocking agents increases the ventilator free days?   \n",
       "1                                                                                                                             Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?   \n",
       "2                                                                                                                          In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?   \n",
       "3   Do patients with moderate-to-severe ARDS have a significance difference in mortality rate beween patients who recieved an early and continous cisatracurium infusion than those with usual care approach with lighter sedation targets?   \n",
       "4                                                                             Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?   \n",
       "5                                                                                                                     Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?   \n",
       "6                                                                                       Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?   \n",
       "7                                                                 Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?   \n",
       "8                                                                                                                                                Prone positioning sessions in patients with severe ARDS significantly decreased mortality?   \n",
       "9                                                                                               Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal voulme decrease mortality?   \n",
       "10                                                                                                Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?   \n",
       "11                                                  A 7-day treatment with low doses of steriods significantly reduced the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events   \n",
       "12                                                                                                       Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?   \n",
       "13                                                                                                                                                   Does steriods hasten the reversal of shock in patients whom had septic shock reversed?   \n",
       "14                                                                                                                                             Does early administration of acetaminophen to treat fever affect the number of ICU-free days   \n",
       "15                                                                                                                                   Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?   \n",
       "16                                                                                                                    Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival   \n",
       "17                                                                                                                            Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?   \n",
       "18                                                                                                                       Hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome   \n",
       "19                                                                                         Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?   \n",
       "20                                                                          In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?   \n",
       "21                               In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33Â°C provide any benefit compared with a targeted temperature of 36Â°C?   \n",
       "22           Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favourable neurologic outcome and reduce mortality?   \n",
       "23                                                    Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?   \n",
       "24                                                    Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?   \n",
       "25                                                                                                                                                         Is there more adverse events in ICU patients who recieved early dexmedetomidine?   \n",
       "26                                                                 Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?   \n",
       "27                                                                                                 Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?   \n",
       "28                                                                                                                                                   Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?   \n",
       "29                                                          At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?   \n",
       "30                                                                                                                            Does routine use of corticosteriods for persistent ARDS over prolonged periods have increased survival rate?    \n",
       "31                                                                                                              Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?   \n",
       "32                                                Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??   \n",
       "33                                                                                                           Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?   \n",
       "34                                             Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?   \n",
       "35                                                                                                is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?   \n",
       "\n",
       "                                                                                                                                       Annotated Docs  \\\n",
       "0                                                                     NBSARDS, ESCNBC, ROSE, ACURASYS, TOF-ARDS, PVOEMVRARDS, ENB, EDPMARDSLPMV, LSPA   \n",
       "1                                                             NBSARDS, ESCNBC, ROSE, ETSDMV, ACURASYS, TOF-ARDS, PVOEMVRARDS, ENB, EDPMARDSLPMV, LSPA   \n",
       "2                                                                                           NBSARDS, ESCNBC, ROSE, ETSDMV, PVOEMVRARDS, TOF-ARDS, ENB   \n",
       "3                                                                                           NBSARDS, ESCNBC, ROSE, ETSDMV, PVOEMVRARDS, TOF-ARDS, ENB   \n",
       "4                                                                                                        ARDSSRDRFMS, FMWSCPARDS, PAC-in-FACTT, FACTT   \n",
       "5                                                                                                        ARDSSRDRFMS, FMWSCPARDS, PAC-in-FACTT, FACTT   \n",
       "6                                                                                                       DLASPEEPvsARDSNET, DIHRFARDSNET, APV, ARDSNet   \n",
       "7                                                                                   DLASPEEPvsARDSNET, SPICE-III, APV, AID-ICU, DIHRFARDSNET, ARDSNet   \n",
       "8                                                                                              PROSEVA, CEIIUPPSARDS, ETSDMV, PPATDSHMA, EDPMARDSLPMV   \n",
       "9                                                                                            SEDCOM, HDDSICU, SPICE-III, OSCILLATE, AID-ICU, MIND-USA   \n",
       "10                                                                        SEDCOM, ANNANE, SPICE-III, ADRENAL, CORTICUS, APPROCCHSS, AID-ICU, MIND-USA   \n",
       "11  SEDCOM, HDDSICU, ANNANE, RDSCI, SPICE-III, ETSDMV, SMDLTSWCI, DDMLSMVICP, ADRENAL, EDvsLSMENDS, CORTICUS, APPROCCHSS, AID-ICU, MIND-USA, ESDDVCIP   \n",
       "12                                                                                                              CORTICUS, APPROCCHSS, ADRENAL, ANNANE   \n",
       "13                                                                                                              CORTICUS, APPROCCHSS, ADRENAL, ANNANE   \n",
       "14                                                                                                                                     ESDDVCIP, HEAT   \n",
       "15                                                                                                                   PROWESS, ESDDVCIP, PROWESS-SHOCK   \n",
       "16                                                                                                                           RUSGATICUD, SAFE, ALBIOS   \n",
       "17                                                                                                                                       SAFE, ALBIOS   \n",
       "18                                                                                                                       RUSGATICUD, ProMISe, AID-ICU   \n",
       "19                                                                                                                   PROWESS, ESDDVCIP, PROWESS-SHOCK   \n",
       "20                                                                                                                                 AID-ICU, TTM, TTM2   \n",
       "21                                                                                                                                          TTM, TTM2   \n",
       "22                                                                                                                                     ESDDVCIP, HACA   \n",
       "23                                                                            RUSGATICUD, SPICE-III, DDMLSMVICP, AID-ICU, RAEATICU, MIND-USA, AUDDICU   \n",
       "24                                                                                                             MIND-USA, SEDCOM, RAEATICU, RUSGATICUD   \n",
       "25                                          HDDSICU, RDSCI, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, AID-ICU, MIND-USA, DIICU, ESDDVCIP   \n",
       "26                                     SEDCOM, RDSCI, RUSGATICUD, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, RAEATICU, MIND-USA, ESDDVCIP   \n",
       "27                     SEDCOM, HDDSICU, RDSCI, RUSGATICUD, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, RAEATICU, MIND-USA, DIICU, ESDDVCIP   \n",
       "28                                                     SEDCOM, HDDSICU, RDSCI, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, DIICU, ESDDVCIP   \n",
       "29                                           SEDCOM, HDDSICU, RDSCI, ETSDMV, SPICE-III, SMDLTSWCI, DDMLSMVICP, EDvsLSMENDS, RAEATICU, DIICU, ESDDVCIP   \n",
       "30                                                                                                                                 ESDDVCIP, ESCPARDS   \n",
       "31                                                                                                                                 ESDDVCIP, LCOTARDS   \n",
       "32                                                                                                                                   ESDDVCIP, MHNOCA   \n",
       "33                                                                                                                                             BTCSCA   \n",
       "34                                                                                                               ESDDVCIP, SPICE-III, HDDSICU, OTCSCA   \n",
       "35                                   SEDCOM, HDDSICU, DPSMVAS, RDSCI, ETSDMV, SPICE-III, DDMLSMVICP, EDvsLSMENDS, RAEATICU, MIND-USA, DIICU, ESDDVCIP   \n",
       "\n",
       "                                                                                                                          Retrieved Docs  \\\n",
       "0                                                    ESCPARDS, FMWSCPARDS, RARDS, ARDSSRDRFMS, EDvsLSMENDS, DDS, APROCCHSS, LSPA, ETSDMV   \n",
       "1                    ESCPARDS, PVOEMVRARDS, TOF-ARDS, HARDST, OSCILLATE, NBSARDS, NEvsVP, LSPA, ETSDMV, ENB, APV, CEIIUPPSARDS, ACURASYS   \n",
       "2                                                     ESCPARDS, PVOEMVRARDS, TOF-ARDS, HARDST, NBSARDS, LSPA, ETSDMV, ENB, APV, ACURASYS   \n",
       "3                                                                                                                     RARDS, HARDST, APV   \n",
       "4                                                                                                                             FMWSCPARDS   \n",
       "5                                                                                    FMWSCPARDS, RARDS, ARDSSRDRFMS, FACTT, PAC in FACTT   \n",
       "6                                                                     RARDS, ARDSNet, HARDST, NBSARDS, LSPA, ENB, CEIIUPPSARDS, ACURASYS   \n",
       "7   ESCPARDS, FMWSCPARDS, ARDSNet, ARDSSRDRFMS, ESDDVCIP, HARDST, EDvsLSMENDS, DLASPEEPvsARDSNET, APROCCHSS, LSPA, ETSDMV, ENB, ACURASYS   \n",
       "8                      ESCPARDS, PVOEMVRARDS, TOF-ARDS, PROSEVA, HARDST, NBSARDS, NEvsVP, LSPA, ETSDMV, ENB, APV, CEIIUPPSARDS, ACURASYS   \n",
       "9                                                      PLMALDHSS, RARDS, ENB, ARDSNet, OSCILLATE, NBSARDS, LSPA, BMIMSARDS, CEIIUPPSARDS   \n",
       "10            Rivers-Trial, ANNANE, THvsTN, PLMALDHSS, FRESHS, CORTICUS, PROWESS-SHOCK, IDEAL-ICU, DDS, APROCCHSS, VASST, ADRENAL, EHPSS   \n",
       "11                                                                                                                               ADRENAL   \n",
       "12                                                                                       ANNANE, PLMALDHSS, CORTICUS, APROCCHSS, ADRENAL   \n",
       "13                                            ADRENAL, ANNANE, FRESHS, SADASS, IDEAL-ICU, PROWESS-SHOCK, DDS, APROCCHSS, VASST, CORTICUS   \n",
       "14                                                                                                                    ITMNCA, HEAT, TTM2   \n",
       "15                                                               PROWESS, PLMALDHSS, SADASS, RDSCI, EDvsLSMENDS, APROCCHSS, ETSDMV, CABS   \n",
       "16                                                                                        SS3vsSS2, ALBIOS, ProCESS, ProMISe, ULS, EHPSS   \n",
       "17                                                                                          FEAST, FRESHS, SADASS, SAFE, HEAT, SEPSISPAM   \n",
       "18                                                                      Rivers-Trial, MPOHCAUSPITHRCA, ProMISe, FACTT, DDS, PAC in FACTT   \n",
       "19                                                                                           APROCCHSS, PROWESS-SHOCK, ANNANE, PLMALDHSS   \n",
       "20                                                                                 ITMNCA, CETHACA, THvsTN, HNPCASR, TTM2, TCAIHCA, HEAT   \n",
       "21                                                                ITMNCA, CETHACA, THvsTN, MPOHCAUSPITHRCA, HNPCASR, TTM2, TCAIHCA, HEAT   \n",
       "22                                                                     ITMNCA, CETHACA, THvsTN, RIC, EXACT, HNPCASR, TCAIHCA, HEAT, HACA   \n",
       "23                                                             DDMLSMVICP, MIND-USA, RUSGATICUD, AID-ICU, AMTD, EDvsLSMENDS, DIICU, LSPA   \n",
       "24                                                                     MIND-USA, RAEATICU, RUSGATICUD, AID-ICU, AMTD, EDvsLSMENDS, DIICU   \n",
       "25                                                                                                 RAEATICU, SEDCOM, RDSCI, DDS, HDDSICU   \n",
       "26                                                                                   ESDDVCIP, RDSCI, EDvsLSMENDS, LSPA, ETSDMV, HDDSICU   \n",
       "27                                                  DDMLSMVICP, ESDDVCIP, RDSCI, EDvsLSMENDS, LSPA, ETSDMV, SMDLTSWCI, PESDCOMV, HDDSICU   \n",
       "28                                                                                                 RAEATICU, SEDCOM, RDSCI, DDS, HDDSICU   \n",
       "29                                                                                         ESDDVCIP, RDSCI, EDvsLSMENDS, ETSDMV, HDDSICU   \n",
       "30                                                         ESCPARDS, PVOEMVRARDS, TOF-ARDS, HARDST, NBSARDS, NEvsVP, LSPA, ENB, ACURASYS   \n",
       "31                                   ESCPARDS, PVOEMVRARDS, TOF-ARDS, HARDST, NBSARDS, NEvsVP, LSPA, ENB, CEIIUPPSARDS, ACURASYS, PTARDS   \n",
       "32                                                                                                                          THvsTN, TTM2   \n",
       "33                                                             CETHACA, HACA-LA, THvsTN, RIC, EXACT, CAC, TTM2, OHCA, IHCA, BTCSCA, HACA   \n",
       "34                                                                         CETHACA, THvsTN, RIC, EXACT, CAC, TTM2, TCAIHCA, BTCSCA, HACA   \n",
       "35                                                                                                                        RDSCI, HDDSICU   \n",
       "\n",
       "    Avg Similarity  Accuracy  Precision    Recall  \n",
       "0         0.852377  0.000000   0.000000  0.000000  \n",
       "1         0.863792  0.277778   0.384615  0.500000  \n",
       "2         0.855618  0.307692   0.400000  0.571429  \n",
       "3         0.817095  0.000000   0.000000  0.000000  \n",
       "4         0.842748  0.000000   0.000000  0.000000  \n",
       "5         0.846286  0.375000   0.428571  0.750000  \n",
       "6         0.846128  0.000000   0.000000  0.000000  \n",
       "7         0.831315  0.055556   0.076923  0.166667  \n",
       "8         0.862781  0.200000   0.230769  0.600000  \n",
       "9         0.852191  0.071429   0.111111  0.166667  \n",
       "10        0.838482  0.166667   0.230769  0.375000  \n",
       "11        0.830840  0.000000   0.000000  0.000000  \n",
       "12        0.825184  0.125000   0.200000  0.250000  \n",
       "13        0.822311  0.076923   0.100000  0.250000  \n",
       "14        0.818425  0.000000   0.000000  0.000000  \n",
       "15        0.848925  0.100000   0.125000  0.333333  \n",
       "16        0.822312  0.000000   0.000000  0.000000  \n",
       "17        0.820228  0.142857   0.166667  0.500000  \n",
       "18        0.850829  0.100000   0.125000  0.333333  \n",
       "19        0.810169  0.000000   0.000000  0.000000  \n",
       "20        0.862389  0.000000   0.000000  0.000000  \n",
       "21        0.868727  0.000000   0.000000  0.000000  \n",
       "22        0.852751  0.100000   0.111111  0.500000  \n",
       "23        0.855470  0.363636   0.500000  0.571429  \n",
       "24        0.817754  0.222222   0.285714  0.500000  \n",
       "25        0.844013  0.066667   0.200000  0.090909  \n",
       "26        0.855043  0.214286   0.500000  0.272727  \n",
       "27        0.849549  0.294118   0.555556  0.384615  \n",
       "28        0.814198  0.153846   0.400000  0.200000  \n",
       "29        0.839352  0.230769   0.600000  0.272727  \n",
       "30        0.843222  0.000000   0.000000  0.000000  \n",
       "31        0.841507  0.000000   0.000000  0.000000  \n",
       "32        0.843517  0.000000   0.000000  0.000000  \n",
       "33        0.833451  0.000000   0.000000  0.000000  \n",
       "34        0.845643  0.000000   0.000000  0.000000  \n",
       "35        0.820172  0.076923   0.500000  0.083333  "
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Read the retrieved documents results from the csv file\n",
    "results_df = pd.read_csv('./outputs/retrieved_docs_results.csv')\n",
    "# Get the average similarity for each question and aggregate the unique Retrieved Documents into a single column\n",
    "analysis_df = get_avg_similarity_df(results_df)\n",
    "# analysis_df = clean_retrieved_files(analysis_df)\n",
    "# load relevant documents\n",
    "relevant_docs_df = pd.read_csv('./outputs/relevant_docs.csv')\n",
    "concatenated_df = get_concatenate_df(analysis_df,relevant_docs_df,topk=36)\n",
    "BM_df = apply_metrics(concatenated_df)\n",
    "BM_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/zhangbobby/Desktop/Capstone/GraphRAG_experiments/.venv/lib/python3.11/site-packages/sklearn/metrics/_ranking.py:1179: UndefinedMetricWarning: No negative samples in y_true, false positive value should be meaningless\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x600 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Numerical Results:\n",
      "Accuracy:  0.103\n",
      "Precision: 0.173\n",
      "Recall:    0.213\n"
     ]
    }
   ],
   "source": [
    "# Example usage\n",
    "metrics_plot = plot_metrics_and_roc(BM_df , score_column='Avg Similarity',threshold = 0.8)\n",
    "metrics_plot.show()\n",
    "\n",
    "# Print numerical results\n",
    "print(\"\\nNumerical Results:\")\n",
    "print(f\"Accuracy:  {BM_df['Accuracy'].mean():.3f}\")\n",
    "print(f\"Precision: {BM_df['Precision'].mean():.3f}\")\n",
    "print(f\"Recall:    {BM_df['Recall'].mean():.3f}\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
